stockmarketproxy
/
ELANNYSE SEC EDGAR

Elanco Animal Health Inc

Pharmaceutical Preparations·INDIANAPOLIS, IN·FY end 12/31·CIK 1739104
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$4.7B$4.4B$4.4B$4.4B$4.8B
Gross Profit$2.6B—————
Operating Income——————
Net Income-$232.0M$338.0M-$1.2B-$65.0M-$472.0M
Operating CF$560.0M$541.0M$271.0M$452.0M$483.0M
Capex$276.0M$147.0M$140.0M$137.0M$126.0M
Free Cash Flow$284.0M$394.0M$131.0M$315.0M$357.0M
Buybacks——————
Dividends——————
Gross Margin55.0%—————
Operating Margin——————
Net Margin-4.9%7.6%-27.9%-1.5%-9.9%
FCF Margin6.0%8.9%3.0%7.1%7.5%
R&D / Revenue7.8%7.7%7.4%7.3%7.7%
Effective Tax-3.6%30.7%-3.0%-47.7%16.8%
Debt / Equity0.571.411.851.551.64
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
ELAN
181:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
ELAN
$15M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
ELAN
-4.9%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%